ES2053413T3 - Peptidos que inducen anticuerpos que neutralizan aislados de vih-1 geneticamente divergentes. - Google Patents

Peptidos que inducen anticuerpos que neutralizan aislados de vih-1 geneticamente divergentes.

Info

Publication number
ES2053413T3
ES2053413T3 ES93890100T ES93890100T ES2053413T3 ES 2053413 T3 ES2053413 T3 ES 2053413T3 ES 93890100 T ES93890100 T ES 93890100T ES 93890100 T ES93890100 T ES 93890100T ES 2053413 T3 ES2053413 T3 ES 2053413T3
Authority
ES
Spain
Prior art keywords
isolates
hiv
peptides
inducing antibodies
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93890100T
Other languages
English (en)
Spanish (es)
Other versions
ES2053413T1 (es
Inventor
Hermann Katinger
Florian Rueker
Gottfried Himmler
Thomas Muster
Martin Purtscher
Georg Maiwald
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Polymun Scientific Immunbiologische Forschung GmbH
Original Assignee
Polymun Scientific Immunbiologische Forschung GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AT98792A external-priority patent/AT403050B/de
Application filed by Polymun Scientific Immunbiologische Forschung GmbH filed Critical Polymun Scientific Immunbiologische Forschung GmbH
Publication of ES2053413T1 publication Critical patent/ES2053413T1/es
Application granted granted Critical
Publication of ES2053413T3 publication Critical patent/ES2053413T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C07K16/1145—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4216—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig
    • C07K16/4225—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig against anti-HIV Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES93890100T 1992-05-14 1993-05-13 Peptidos que inducen anticuerpos que neutralizan aislados de vih-1 geneticamente divergentes. Expired - Lifetime ES2053413T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT98792A AT403050B (de) 1992-05-14 1992-05-14 Peptide, die antikörper binden
US93278792A 1992-08-29 1992-08-29

Publications (2)

Publication Number Publication Date
ES2053413T1 ES2053413T1 (es) 1994-08-01
ES2053413T3 true ES2053413T3 (es) 1997-11-16

Family

ID=25594514

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93890100T Expired - Lifetime ES2053413T3 (es) 1992-05-14 1993-05-13 Peptidos que inducen anticuerpos que neutralizan aislados de vih-1 geneticamente divergentes.

Country Status (6)

Country Link
US (3) US5693752A (esLanguage)
EP (1) EP0570357B1 (esLanguage)
JP (1) JP3369246B2 (esLanguage)
CA (1) CA2096159C (esLanguage)
DE (2) DE570357T1 (esLanguage)
ES (1) ES2053413T3 (esLanguage)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0580758A4 (en) * 1991-04-18 1995-04-05 Sinai School Medicine RECOMBINANT ANTIBODIES AGAINST HUMAN IMMUNE WEAKNESS VIRUS.
CA2096159C (en) * 1992-05-14 2004-07-20 Hermann Katinger Peptides that induce antibodies which neutralize genetically divergent hiv-1 isolates
DE69426725T2 (de) * 1993-09-11 2001-09-06 Polimun Scientific Immunbiologische Forschungsgesellschaft Mbh, Wien Peptide, die neutralisierende antikörper gegen genetisch divergierende hiv-1 stämme, induzieren
FR2731225B1 (fr) * 1995-03-03 2003-10-31 Pasteur Institut Peptides de glycoproteine transmembranaire d'enveloppe et de proteine de capside du retrovirus humain du type hiv-1 et peptides presentant avec eux une parente immunologique
CN1147586C (zh) 1994-10-20 2004-04-28 巴斯德研究所 Hiv-1 o组(或亚组)逆转录病毒抗原的核苷酸序列
GB9424631D0 (en) * 1994-12-06 1995-01-25 Lynxvale Ltd Modulating the immune response
WO1996033219A1 (en) * 1995-04-19 1996-10-24 Polymun Scientific Immunbiologische Forschung Gmbh Monoclonal antibodies against hiv-1 and vaccines made thereof
US5891994A (en) * 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
US6492110B1 (en) 1998-11-02 2002-12-10 Uab Research Foundation Reference clones and sequences for non-subtype B isolates of human immunodeficiency virus type 1
JP4441595B2 (ja) 1998-06-12 2010-03-31 マウント シナイ スクール オブ メディシン オブ ニューヨーク ユニバーシティー インターフェロン誘導性の遺伝子工学的に作製された弱毒ウイルス
DE69934885T2 (de) 1998-06-12 2007-11-08 Mount Sinai School Of Medicine Of The City University Of New York Neue methoden und interferon defiziente substrate zur vermehrung von viren
US7090848B1 (en) * 1998-08-04 2006-08-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine HIV-1 envelope protein associated with a broadly reactive neutralizing antibody response
WO2000007631A1 (en) * 1998-08-04 2000-02-17 The Henry M. Jackson Foundation Expression and characterization of hiv-1 envelope protein associated with a broadly reactive neutralizing antibody response
US7115262B1 (en) 1999-03-16 2006-10-03 The United States Of America As Represented By The Department Of Health And Human Services Chimeric protein for prevention and treatment of HIV infection
US6635416B2 (en) * 2000-04-10 2003-10-21 Mount Sinai School Of Medicine Of New York University Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
US6399067B1 (en) * 2000-04-28 2002-06-04 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
JP4495969B2 (ja) * 2002-01-17 2010-07-07 ポリマン サイエンティフィック イミューンバイオロジッシュ フォーシュング ゲゼルシャフト ミット ベシュレンクテル ファフツング Ｈｉｖ−１中和抗体を誘導する抗イディオタイプ抗体
JP2007515394A (ja) * 2003-05-06 2007-06-14 ザ スクリプス リサーチ インスティチュート ドメイン交換結合分子、その使用方法および製造方法
DK1773384T3 (en) 2004-06-01 2015-11-23 Us Agriculture GM swine influenza virus and uses thereof
JP2008535783A (ja) 2005-02-15 2008-09-04 サイモン・エル・エル・シー Ｈｉｖ−１の増殖を弱めるための方法および組成物
EP1855713B1 (en) * 2005-02-15 2016-04-27 Mount Sinai School of Medicine Genetically engineered equine influenza virus and uses thereof
AU2006235507B2 (en) * 2005-04-12 2012-08-30 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
EP1989326A4 (en) 2006-01-17 2009-09-30 Health Research Inc BIO-HETERODUPLEX TRACKING TEST
WO2008127651A1 (en) * 2007-04-13 2008-10-23 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
EP2550362B1 (en) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
SI2691530T1 (en) 2011-06-10 2018-08-31 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
WO2015048635A1 (en) 2013-09-27 2015-04-02 Duke University Mper-liposome conjugates and uses thereof
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
AU2016222962B2 (en) 2015-02-26 2020-05-21 Boehringer Ingelheim Vetmedica Gmbh Bivalent swine influenza virus vaccine
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
JP2019509046A (ja) 2015-12-05 2019-04-04 サントル オスピタリエ ユニヴェルシテール ヴォドアＣｅｎｔｒｅ Ｈｏｓｐｉｔａｌｉｅｒ Ｕｎｉｖｅｒｓｉｔａｉｒｅ Ｖａｕｄｏｉｓ Ｈｉｖ結合剤
WO2020012435A1 (en) 2018-07-13 2020-01-16 Lausanne University Hospital Hiv binding agents
US20220267416A1 (en) 2019-07-15 2022-08-25 Lausanne University Hospital Hiv binding agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01501547A (ja) * 1986-06-12 1989-06-01 バイオジェン　ナームローズ　ベンノットシャップ Ｈｉｖ感染の病因に関するペプチド
EP0330359A3 (en) * 1988-02-25 1991-06-05 Bio-Rad Laboratories, Inc. Composition useful in the diagnosis and treating of hiv-1 infection
ZA896410B (en) * 1988-08-27 1990-05-30 Akzo Nv Synthetic peptides immunochemically reactive with hiv-antibodies
CA2096159C (en) * 1992-05-14 2004-07-20 Hermann Katinger Peptides that induce antibodies which neutralize genetically divergent hiv-1 isolates

Also Published As

Publication number Publication date
US5866694A (en) 1999-02-02
EP0570357B1 (en) 1997-06-25
EP0570357A2 (en) 1993-11-18
DE570357T1 (de) 1994-07-28
JPH06293797A (ja) 1994-10-21
EP0570357A3 (esLanguage) 1994-04-20
DE69311764D1 (de) 1997-07-31
US5693752A (en) 1997-12-02
CA2096159A1 (en) 1993-11-15
JP3369246B2 (ja) 2003-01-20
DE69311764T2 (de) 1998-02-05
US5756674A (en) 1998-05-26
ES2053413T1 (es) 1994-08-01
CA2096159C (en) 2004-07-20

Similar Documents

Publication Publication Date Title
ES2053413T3 (es) Peptidos que inducen anticuerpos que neutralizan aislados de vih-1 geneticamente divergentes.
ES2139017T3 (es) Compuestos que inhiben la replicacion del vih.
ES2002490A6 (es) Un metodo de preparar un virus recombinante
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
ES2124532T3 (es) Sistema vector-huesped utilizable en terapia genica.
NO951212D0 (no) Humane nöytraliserende monoklonale antistoffer mot humant immunsviktvirus
ES2173314T3 (es) Metodos y composiciones para la modificacion selectiva de acidos nucleicos.
ES2074042T3 (es) Exotoxina recombinante de pseudomonas construccion de una inmunotoxina activa con efectos secundarios menores.
TR199902426T2 (xx) Bitki b�ceklerinin kontrol�.
ES2045475T3 (es) Rna del genoma del virus de la hepatitis no-a, no-b, cdna y proteina del antigeno del virus.
AR123206A1 (es) Terapia génica
EA200100302A1 (ru) Способы и композиции для протективной и терапевтической генетической иммунизации
DE69318136D1 (de) Sulfonsaeurederivate zur behandlung von viruserkrankungen
MX9300304A (es) Peptidos insecticidamente efectivos.
EA199901024A1 (ru) Фармацевтическая антивирусная композиция, содержащая глицирризиновую кислоту и, по меньшей мере, один белок, обладающий антивирусной активностью
ES2072928T3 (es) Antigenos de celulas de islotes pancreaticos obtenidos por clonaje molecular.
ES2052589T3 (es) Vector viral, codificante para una glicoproteina del virus responsable del sida, vacuna y anticuerpo.
ES2062521T3 (es) Peptidos sinteticos para una vacuna contra hiv-1.
ES2118242T3 (es) Vacunas anti virus de la inmunodeficiencia felina (fiv).
ES2156902T3 (es) Peptidos que inducen la produccion de anticuerpos neutralizantes contra cepas de vih-1 geneticamente divergentes.
ES8800985A1 (es) Procedimiento de preparar proteinas.
PT817858E (pt) Preparacoes fotoprotectoras que compreendem derivados de triazina
DE69330268D1 (de) Hämoregulierende peptide
ES2062990T3 (es) Vacunas, que contienen la proteina f del virus del sida.
ES2169040T3 (es) Planta resistente a dos o mas virus y preparacion de la misma.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 570357

Country of ref document: ES